Genentech Completes iNeST Facility in Oregon
Genentech Completes iNeST Facility in Oregon
Attachment: Map
Genentech, the first publicly owned biotechnology company, recently completed an individualized neoantigen-specific immunotherapy (iNeST) facility on its campus in Hillsboro, Oregon. Using proprietary algorithms, the iNeST process involves DNA extraction from an individual patient's tumor cells and sequences, according to the company.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- California Dreamin': Life Sciences Sector to Invest Nearly $1 Billion for 3...
- Pharma-Biotech Industry Capital Investment Tops $5 Billion for First-Quarte...
- Washington State Sees $13.8 Billion Worth of Projects Under Construction
- Jacobs Solutions Has Hand in $75 Billion Worth of U.S. Projects
- Suffolk Construction at Work on $3.2 Billion in U.S. Projects